Biden Regulatory Freeze May Pause SUNSET Rule
Executive Summary
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
You may also be interested in...
Pending Litigation Delays Implementation Of SUNSET Regulation Review Policy To 2022
HHS says trying to implement the rule while it is still being litigated could create confusion for the public, among other problems.
Two-Tier Specialty Drug Policy: Part D Plans Gain Formulary Flexibility But Impact May Be Limited
Use of preferred and non-preferred specialty formulary tiers will be allowed but preferred tiers are not necessarily limited to generics and biosimilars and coinsurance for non-preferred specialty drugs cannot exceed 33%.
US Regulatory SUNSET Misses FDA’s OTC Drug Regulations, But Reaches Supplement Rules
Expiration dates in HHS’ final SUNSET rule exclude OTC drugs after CCHPA and other groups argue the rule would create more problems than it would solve. But dietary supplement regulations are subject to the rule.